Alphaketoglutarate-based polyester additives for wound healing
Innovative polyester additives using alpha-ketoglutarate (aKG) for enhanced wound healing. These additives ensure sustained release of aKG, a pro-regenerative molecule, leading to effective healing without side effects. Economical production with minimal application dosage.
Overview
Axilea LLC introduces a novel approach to wound healing using alphaketoglutarate (aKG)-based polyester additives. These additives are designed to facilitate the sustained release of aKG, a naturally occurring pro-regenerative molecule, enhancing the healing of everyday cuts and bruises. The polyester form of aKG is crucial to its efficacy, as it ensures a gradual release that promotes tissue regeneration effectively. The production process is highly economical, capable of generating large quantities within days, yet requires only micrograms per application.
Technical specifications
Key features:
- Utilizes alpha-ketoglutarate (aKG), integrated into a polyester form for effective therapeutic release
- Incorporates a diol molecule, metabolized through the alcohol dehydrogenase pathway, ensuring no adverse side effects
- Production capacity of hundreds of grams within 2-3 days, with applications requiring minimal dosage
Applications:
- Designed for incorporation into wound dressings such as gauze
- Targeted for everyday use on cuts and bruises, leveraging natural metabolic pathways for efficacy
Technology readiness level
Currently, the technology is at TRL 4, with ongoing validation efforts focused on assessing toxicity profiles in large animal models. Future plans include demonstrating incorporation into medical gauze for practical applications. The strategic location near Case Western Reserve University and Cleveland Clinic enables collaboration opportunities for further development.
About Axilea LLC
Axilea LLC, which operates as ImmunoMetabolix, is a clinical-stage biotechnology company that utilizes a proprietary engineering approach to develop metabolically-fit immunotherapies. The company focuses on addressing cancer, autoimmune, and inflammatory diseases where existing treatments may be ineffective, costly, or cause significant side effects. By targeting metabolic dysfunctions that can impair the immune system, their core technology, the iMET platform, is designed to generate more potent T-cells capable of specifically killing cancer cells or inhibiting inflammatory processes.
The company's work aims to provide enhanced therapeutic efficacy and patient safety for those suffering from complex immune-related disorders. Originally spun out of research at Arizona State University, the organization works to translate advancements in cell metabolism into actionable healthcare solutions. By focusing on the metabolic fitness of immune cells, the company seeks to offer patients improved outcomes and better quality of life through novel, patient-centric clinical interventions.
Inquire about this partnering listing
Industry applications
delivered to your inbox.